Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06356311 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06356311 · ClinicalTrials.gov record · last posted 2026-02-27

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

Study acronym: TroFuse-015
StatusActive, Not Recruiting
PhasePhase 3
Started2024-05-03
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This study will compare how safe and effective sacituzumab tirumotecan is versus the treatment of physician's choice (TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumotecan is superior to TPC with respect to Overall Survival (OS).

Amendment record 47 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 47 times since 2024-04-04; most recent amendment 2026-02-24. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2026-02-02
Status change Recruiting→Active, Not Recruitingv45
2024-05-10
Status change Not Yet Recruiting→Recruitingv3
Trial Details
NCT Number NCT06356311
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Gastroesophageal Cancer
Enrollment 450 participants
Start Date 2024-05-03
Primary Completion 2027-01-04 (estimated)
Study Completion 2027-05-06 (estimated)
Updated on ClinicalTrials.gov 2026-02-27